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The reply from Kalogerakos [1] to our article has high-
lighted the importance of the need to understand the risk
conferred by BRCA mutation carriers in Chinese and other
ethnic groups in order to achieve personalized medicine.
Guidelines for prophylactic interventions and intensive
surveillance are based on studies performed mainly in
Caucasian cohorts. BRCA1 and BRCA2 mutation carriers
have a 4.5-fold and 3.4-fold increased risk of getting
contralateral breast cancer. The relative risk of contralat-
eral breast cancer in BRCA1 mutation carriers increases as
the age at ﬁrst diagnosis decreases, and can be as high as
11-fold if the age at ﬁrst diagnosis of breast cancer is under
35 [2]. Occult invasive cancers found in prophylactic
mastectomy specimens ranges from 0.7 to 10.7%. Pro-
phylactic mastectomy is found to be effective in preventing
invasive breast cancer in BRCA mutation carriers as the
remaining risk is less than 0.2% per woman-year [3].
Similarly, salpingo-oophorectomy signiﬁcantly reduces the
risk of breast cancer (hazard ratio [HR] = 0.36-0.63) and
ovarian or fallopian tube cancer (HR = 0.14-0.28) in
BRCA mutation carriers. There is also reduction in breast
cancer (HR = 0.44) and ovarian cancer-speciﬁc mortality
(HR = 0.21) [4]. However, there is limited information on
BRCA2 mutation carriers since it is less common in
Caucasian cohorts. Because of a lower incidence of breast
cancer in Chinese (1 in 20) and also a higher BRCA2
detection rate found in our study, risk in this group is likely
to be different. Therefore, it is important to have more
precise ethnicity-speciﬁc estimates of speciﬁc risks so that
more accurate guidelines based on the efﬁcacy of risk-
reducing interventions, surveillance, and use of novel drugs
such PARP inhibitors can be made.
Next-generation sequencing technology (also known as
massive parallel sequencing) allows the development of
studies unachievable a few years ago. Nowadays, next-
generation sequencing technology provides an unprece-
dented ability to search for mutations, copy number aber-
rations, and somatic rearrangements in an entire cancer
genome at base pair resolution which can be performed in a
matter of weeks. By comparing BRCA mutations carriers
who do not develop cancer with those who do, it may be
possible to identify novel genetics changes associated with
development of BRCA-related breast/ovarian and related
cancers. As sequencing capacity improves, scientists will
move forward from one genome per individual to multiple
genomes per individual from sources including precan-
cerous cells and cancer cells. Furthermore, recent genome-
wide association studies using high-throughput human SNP
arrays also identiﬁed new breast cancer susceptibility genes
which can increase cancer risk prediction [5, 6]. As the
complexity of assessing cancer risk genetically increases in
technology and knowledge of ethnic differences, clinical
recommendations will need to be standardized and per-
sonalized accordingly.
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